Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 18.40% | Reduce −9.3% | 1,940,993 | $73.00 | $142M | −197,970 | −$2M |
| FOLD - Amicus | 11.30% | Reduce −9.8% | 8,145,311 | $10.68 | $87M | −884,532 | −$3M |
| BMRN - Biomarin Pharmaceutical | 9.95% | Reduce −3.5% | 1,090,056 | $70.29 | $77M | −40,111 | −$16M |
| UTHR - United Therapeutics | 8.53% | Reduce −31.3% | 183,246 | $358.35 | $66M | −83,668 | −$19M |
| BIIB - Biogen | 5.76% | Reduce −20.8% | 228,916 | $193.84 | $44M | −60,134 | −$23M |
| Staar Surgical | 5.27% | Reduce −21.0% | 1,091,608 | $37.15 | $41M | −290,011 | −$25M |
| ACAD - Acadia Pharmaceuticals | 5.04% | Add +4.3% | 2,523,956 | $15.38 | $39M | +105,115 | −$488K |
| ALNY - Alnylam Pharmaceuticals | 5.03% | New | 140,681 | $275.03 | $39M | +140,681 | +$39M |
| PRTA - Prothena | 3.78% | Add +4.3% | 1,737,964 | $16.73 | $29M | +71,586 | −$5M |
| IOVA - Iovance Biotherapeutics | 3.71% | Add +43.7% | 3,041,685 | $9.39 | $29M | +925,282 | +$12M |
| ANAB - Anaptysbio | 3.67% | Add +5.0% | 843,971 | $33.50 | $28M | +40,330 | +$8M |
| Sarepta Therapeutics | 3.41% | Add +4.3% | 210,258 | $124.89 | $26M | +8,575 | −$6M |
| ALKS - Alkermes | 1.40% | Reduce −22.4% | 384,656 | $27.99 | $11M | −110,936 | −$1M |
| PTC - Ptc Therapeutics | 1.27% | New | 264,469 | $37.10 | $10M | +264,469 | +$10M |
| ALGN - Align Technology | 1.25% | Hold | 37,772 | $254.32 | $10M | — | — |
| EHTH - Ehealth | 1.24% | Reduce −0.1% | 2,347,519 | $4.08 | $10M | −2,671 | −$1M |
| NVCR - Novocure | 1.21% | Add +5.6% | 593,540 | $15.63 | $9M | +31,632 | −$348K |
| Acelyrin | 1.15% | Add +4.5% | 1,792,895 | $4.93 | $9M | +77,715 | +$1M |
| Revance Therapeutics | 1.09% | Reduce −69.3% | 1,611,787 | $5.19 | $8M | −3,645,299 | −$5M |
| SNDX - Syndax Pharmaceuticals | 1.01% | Hold | 405,193 | $19.25 | $8M | — | — |
| Sage Therapeutics | 0.95% | Hold | 1,010,833 | $7.22 | $7M | — | — |
| Gossamer Bio | 0.80% | Hold | 6,277,093 | $0.9864 | $6M | — | — |
| Karyopharm Therapeutics | 0.55% | Hold | 5,102,193 | $0.8300 | $4M | — | — |
| Nevro | 0.54% | Hold | 750,371 | $5.59 | $4M | — | — |
| BNTX - Biontech Se- | 0.39% | New | 25,206 | $118.77 | $3M | +25,206 | +$3M |
| Verve Therapeutics | 0.36% | Hold | 575,817 | $4.84 | $3M | — | — |
| EW - Edwards Lifesciences | 0.34% | New | 39,473 | $65.99 | $3M | +39,473 | +$3M |
| MIRM - Mirum Pharmaceuticals | 0.33% | Hold | 64,700 | $39.00 | $3M | — | — |
| RLMD - Relmada Therapeutics | 0.31% | Hold | 732,400 | $3.24 | $2M | — | — |
| NUVB - Nuvation Bio · CL A | 0.23% | Hold | 772,652 | $2.29 | $2M | — | — |
| TSHA - Taysha Gene Therapies | 0.21% | Hold | 811,268 | $2.01 | $2M | — | — |
| TVTX - Travere Therapeutics | 0.20% | Hold | 110,719 | $13.99 | $2M | — | — |
| STOK - Stoke Therapeutics | 0.20% | Hold | 125,861 | $12.29 | $2M | — | — |
| BCYC — | 0.18% | New | 59,582 | $22.63 | $1M | +59,582 | +$1M |
| HUM - Humana | 0.16% | Hold | 3,985 | $316.74 | $1M | — | — |
| ALDX - Aldeyra Therapeutics | 0.16% | Hold | 225,465 | $5.39 | $1M | — | — |
| Vyne Therapeutics Pipe | 0.11% | Hold | 445,434 | $1.88 | $837K | — | — |
| Elevation Oncology | 0.10% | Reduce −27.9% | 1,298,097 | $0.5999 | $779K | −502,009 | −$4M |
| Instil Bio | 0.10% | New | 11,165 | $67.32 | $752K | +11,165 | +$752K |
| ACRS - Aclaris Therapeutics | 0.09% | Hold | 569,832 | $1.15 | $655K | — | — |
| PYXS - Pyxis Oncology | 0.08% | New | 170,000 | $3.67 | $624K | +170,000 | +$624K |
| Generation Bio | 0.05% | Hold | 150,475 | $2.47 | $372K | — | — |
| Bluebird Bio | 0.04% | Reduce −87.0% | 604,260 | $0.5195 | $314K | −4,029,091 | −$4M |
| URGN - Urogen Pharma | 0.04% | Hold | 24,500 | $12.70 | $311K | — | — |
| ABEO - Abeona Therapeutics | 0.01% | New | 12,865 | $6.32 | $81K | +12,865 | +$81K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ALNY - Alnylam Pharmaceuticals | 5.16% | Exit | 0 | $243.00 | $44M | −183,123 | −$44M |
| CYTK - Cytokinetics | 0.70% | Exit | 0 | $54.18 | $6M | −111,717 | −$6M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2